Corning Life Sciences is scaling the adoption of organoids by providing specialized reagents and automated protocols that address critical barriers in standardization and reproducibility. These advancements allow biotech developers to leverage human-relevant systems that better predict clinical outcomes, moving beyond the traditional reliance on animal models now supported by the FDA Modernization Act 2.0. Standardized workflows and high-throughput organoid platforms will be essential as these human-centric models transition from academic research into mainstream pharmaceutical pipelines.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
